Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Hired: G. Allen Nickols as VP of biology, formerly director of pharmacology at the Pfizer Inc.'s global R&D unit
WIR Staff
cancer
Cardiovascular
Diagnostic...
Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Appointed: Gregory Johnson, managing director at Prolog Ventures; John Rice, managing partner at Triathlon Medical Ventures; and Martin Sanders, a venture partner at Charter Life Sciences...
...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate... ...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos... ...Princeton, N.J.) rights to KI-0002 in exchange for an upfront fee, plus milestones and royalties. Kereos Inc....
...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate... ...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...
Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Hired: G. Allen Nickols as VP of biology, formerly director of pharmacology at the Pfizer Inc.'s global R&D unit
WIR Staff
cancer
Cardiovascular
Diagnostic...
Kereos Inc. , St. Louis, Mo. Business: Cardiovascular, Diagnostic, Cancer Appointed: Gregory Johnson, managing director at Prolog Ventures; John Rice, managing partner at Triathlon Medical Ventures; and Martin Sanders, a venture partner at Charter Life Sciences...
...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate... ...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos... ...Princeton, N.J.) rights to KI-0002 in exchange for an upfront fee, plus milestones and royalties. Kereos Inc....
...DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate... ...portfolio for use with other applications. Financial terms were not disclosed. Under a 2002 deal, Kereos...